Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Accumulated Expenses (2020 - 2025)

Insight Molecular Diagnostics (IMDX) has disclosed Accumulated Expenses for 6 consecutive years, with $1.1 million as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses changed 0.0% to $1.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.1 million through Dec 2025, changed 0.0% year-over-year, with the annual reading at $1.1 million for FY2025, 0.0% changed from the prior year.
  • Accumulated Expenses hit $1.1 million in Q4 2025 for Insight Molecular Diagnostics, down from $2.2 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $4.1 million in Q3 2022 to a low of $1.1 million in Q1 2024.
  • Historically, Accumulated Expenses has averaged $2.2 million across 5 years, with a median of $2.1 million in 2023.
  • Biggest five-year swings in Accumulated Expenses: skyrocketed 138.29% in 2021 and later crashed 57.66% in 2023.
  • Year by year, Accumulated Expenses stood at $2.8 million in 2021, then plummeted by 37.35% to $1.8 million in 2022, then decreased by 6.89% to $1.6 million in 2023, then plummeted by 32.32% to $1.1 million in 2024, then changed by 0.0% to $1.1 million in 2025.
  • Business Quant data shows Accumulated Expenses for IMDX at $1.1 million in Q4 2025, $2.2 million in Q3 2025, and $1.5 million in Q2 2025.